-+ 0.00%
-+ 0.00%
-+ 0.00%

Camurus says Health Canada approves Oczyesa XR for acromegaly maintenance therapy

PUBT·10/12/2026 07:03:08
Camurus says Health Canada approves Oczyesa XR for acromegaly maintenance therapy
  • Health Canada cleared Camurus’ Oczyesa XR, a monthly subcutaneous octreotide depot, for maintenance treatment of adult acromegaly patients.
  • Approval covers patients who responded to, tolerated somatostatin analog therapy; product can be self-administered at home via injection pen.
  • Decision relied on seven studies, including Phase 3 ACROINNOVA 1 and 2 showing IGF-1 control with a safety profile comparable to peers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camurus AB published the original content used to generate this news brief via Cision (Ref. ID: 202610120300BITN____UKPR__SV_20261011-BIT-1734-0) on October 12, 2026, and is solely responsible for the information contained therein.